PT - JOURNAL ARTICLE AU - Zhang, Jiqin AU - Hu, Yongxian AU - Yang, Jiaxuan AU - Li, Wei AU - Tian, Yue AU - Wei, Guoqing AU - Zhang, Linjie AU - Zhao, Kui AU - Qi, Yalei AU - Tan, Binghe AU - Zhang, Mingming AU - Li, Yi AU - Tian, Qiliang AU - Fang, Chunqian AU - Wu, Yuxuan AU - Li, Dali AU - Du, Bing AU - Liu, Mingyao AU - Huang, He TI - Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphoma AID - 10.1101/2020.09.22.20199786 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.22.20199786 4099 - http://medrxiv.org/content/early/2020/09/23/2020.09.22.20199786.short 4100 - http://medrxiv.org/content/early/2020/09/23/2020.09.22.20199786.full AB - In recent years, chimeric antigen receptor (CAR) T cell therapy has shown great promise in treating hematological malignancies. However, using virus in manufacture of CAR T cells brings about several problems. The application of CRISPR/Cas9 genome editing technology emerges in constructing novel CAR T cells by disrupting endogenous genes. Here we successfully develop a two-in-one approach to generate non-viral genome specific targeted CAR T cells through CRISPR/Cas9. By targeting a CAR in AAVS1 safe harbor locus, we demonstrated that these CAR T cells behave comparable to those conventionally produced by lentivirus. Furthermore, PD1-knockin anti-CD19 CAR T cells show a superior ability to eradicate tumor cells with high PD-L1 expression. In the adoptive therapy for relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL), we observed durable responses without serious adverse events and complete remission (CR) in patients treated with these PD1 knockout CAR T cells. Collectively, our results prove the safety and feasibility of non-viral genome specific integrated CAR T cells, thus providing a new potential strategy for cancer treatment using these novel CAR T cells.Competing Interest StatementThis work was paritally suppored by Bioray Laboratories Inc. Patents related to this manuscript have been applied.Clinical TrialNCT04213469Funding StatementThis work was supported by National Key R&D Program of China (2019YFA0802802) and the National Natural Science Foundation of China (91857116, 31871453). This work was also paritally suppored by Bioray Laboratories Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was reviewed and approved by the Clinical Research Ethics Committee of the First Affliated Hospital, College of Medicine, Zhejiang University reference number: 2020IIT(85)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data that supported the findings of this study are available from the corresponding author upon reasonable request.